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ABSTRACT
Objectives: To describe loss to follow-up (LTFU) at all
stages of the HIV programme.
Design: A retrospective cohort study.
Setting: The HIV clinic at Hospital National Simão
Mendes in Bissau, Guinea-Bissau.
Participants: A total of 4080 HIV-infected patients.
Outcome measures: Baseline characteristics,
percentages and incidence rates of LTFU as well as
LTFU risk factors at four different stages: immediately
after HIV diagnosis (stage 1), after the first CD4 cell
count and before a follow-up consultation (stage 2),
after a follow-up consultation for patients not eligible
for antiretroviral treatment (ART; stage 3) and LTFU
among patients on ART (stage 4).
Results: Almost one-third of the patients were lost to
the programme before the first consultation where ART
initiation is decided; during the 7-year observation
period, more than half of the patients had been lost to
follow-up (overall incidence rate=51.1 patients lost per
100 person-years). Age below 30 years at inclusion
was a risk factor for LTFU at all stages of the HIV
programme. The biggest risk factors were body mass
index <18.5 kg/m2 (stage 1), male gender (stage 2),
HIV-2 infection (stage 3) and CD4 cell count <200
cells/μL (stage 4).
Conclusions: In this study, LTFU constituted a major
problem, and this may apply to other similar ART
facilities. More than half of the patients were lost to
follow-up shortly after enrolment, possibly implying a
high mortality. Thus, retention should be given a high
priority.
INTRODUCTION
An estimated 34 million people are infected
with HIV and the number is growing.
Sub-Saharan Africa is the most affected
region, and in some areas antiretroviral
treatment (ART) is not available. The cover-
age of ART is lowest in West and Central
Africa where only 30% of the patients in
need of ART actually receive it.1
ART has signiﬁcantly reduced mortality and
improved life expectancy of HIV-infected
patients,2 but the success critically depends
on regular patient follow-up.3 ART requires a
large commitment from the patient and
without good adherence viral resistance will
develop.4 5 Adherence to treatment may be
considered more important than the potency
of any ART regimen.6 Loss to follow-up
(LTFU) of HIV-infected patients is closely
related to ARTadherence and is becoming an
increasing problem in sub-Saharan Africa as
ART programmes expand and staff-to-patient
ratios decrease.7 8 In a systematic review of
ART in sub-Saharan Africa, the authors found
that up to 40% of patients were lost to
follow-up, with large variation in retention
rates between programmes.9 The risk of
LTFU is usually highest during the ﬁrst
6 months after starting ART.8 Furthermore,
mortality among patients lost to follow-up in
sub-Saharan settings has been reported to
range from 20% to 87%.3 This implies that
standard survival analyses that censor
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▪ First study on loss to follow-up (LTFU) among
HIV-infected patients in Guinea-Bissau.
▪ Describes LTFU at all stages of the HIV
programme.
▪ Large dataset with several years of follow-up.
▪ Active follow-up was limited to telephone calls.
▪ Missing data from a number of patients.
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follow-up time at the last visit to an HIV clinic will under-
estimate the overall mortality.10 11
Regular monitoring is needed to determine when to
start ART,12 13 and high rates of LTFU before this initi-
ation have been reported in several African settings.14–16
However, little information is available about LTFU in
patients not eligible for ART and the outcome of these
patients in sub-Saharan Africa.
The term ‘loss to programme’ covers patient mortality,
LTFU and patients transferring to another HIV clinic. A
recent meta-analysis of loss to programme in sub-Saharan
Africa has described that patients may become lost to
follow-up at different stages. Going though six studies with
a total inclusion of 58 746 patients diagnosed with HIV,
the authors found that 72% of the patients had a CD4 cell
count measured, 40% were eligible for ART and only 25%
of the patients initiated ART.17 A systematic review found
large variations in LTFU between these stages.18
There is an urgent need to understand why patients
are lost to follow-up.19 20 A better understanding of risk
factors for tracing success and mortality among these
patients could help to develop targeted interventions to
prevent LTFU.21 This understanding may be achieved by
describing the epidemiology and risk factors of LTFU.
As the extent and causes of LTFU may differ between
patients at different stages,17 18 the description should
be made by stratifying patients into these groups. The
aim of this study was to describe the epidemiology of
LTFU including risk factors in patients at all stages of an
HIV programme.
METHODS
Setting and patients
All patients treated according to the national guidelines
from an HIV clinic at Hospital National Simão Mendes
(HNSM) in Bissau, the capital of Guinea-Bissau, were
included in this retrospective cohort study. The out-
patient ART centre of HNSM is the largest ART centre
in Guinea-Bissau. The study population consisted of
HIV-infected individuals diagnosed at the HIV clinic at
HNSM between 1 June 2005 and 1 June 2012. Patients
diagnosed with HIV in the period 1 March 2011 to
1 June 2012 who were not eligible to ART were excluded
from the analyses, as they did not have 210 days of
follow-up and could therefore not be considered either
LTFU or on follow-up.
At the ﬁrst visit to the clinic, HIV testing was per-
formed and basic demographic information was col-
lected. Schooling was deﬁned as attending classes with
the purpose of learning how to read; Koranic schools
were not included in this deﬁnition. At the day of HIV
diagnosis, patients were given a requisition for laboratory
analyses (CD4 cell count, biochemistry and haematol-
ogy). The blood samples were usually drawn at the clinic
the following day and the patients were asked to return
to the clinic within 7 days. At this consultation, the deci-
sion to initiate ART was made based on WHO
guidelines. If ART initiation was decided, the patients
received ART the same day as the consultation. All ser-
vices, including ART, were free of charge for all
HIV-infected patients.
Active follow-up
When diagnosed with HIV, the patients were provided
with a unique registration number and a personal card
stating the date of next appointment at the clinic. At
HIV diagnosis, all patients were asked to provide their
own telephone number and the number of a contact
person to be used during active follow-up. Patients on
ART were contacted if they had not been at the clinic
for 3 months after the date of the last visit, and patients
not eligible for ART were contacted if they had not been
at the clinic for 180 days. Patient contact by telephone
was attempted at least twice on two separate days.
Loss to follow-up
Patients on ART were considered lost to follow-up if they
had not visited the clinic for 90 days (60 days after the
next appointment),while patients without treatment were
noted as LTFU if they had not been at the clinic for
7 months (1 month after the date of the next appoint-
ment). Information on patient mortality and clinic trans-
fer was collected by personal information and telephone
calls with contact persons and from the hospital wards.
Patient conﬁdentiality was at no point broken.
Laboratory methods
Venous blood samples were collected for biochemical
analyses (alanine aminotransferase, aspartate transamin-
ase, creatinine) and haematology (haemoglobin, CD4
cell count, platelets). Orphée, Mythic, Diamond
Diagnostics, USA was used to measure haematology. For
biochemical analyses, the Reﬂotron Plus System, Roche
diagnostics or BA-88 Mindray biochemistry analyser was
used. CD4 cell counts were performed by ﬂow cytometry
using Partec CyFlow SL_3 (Cyﬂow SL, Partec, Munster,
Germany). HIV screening was carried out with a rapid
test in the clinic (Determine HIV-1/2 assay (Abbott
Laboratories, 72 Abbott Park, Illinois, USA) and con-
ﬁrmation and discrimination using SD Bioline HIV 1/2
3.0 (Standard Diagnostics Inc, Kyonggi-do, South
Korea). As conﬁrmation, an additional Bioline test was
performed at the National Public Health Laboratory
according to the standard recommendations from the
National HIV programme of Guinea-Bissau.
Statistical methods
We compared the demographic, clinical and laboratory
features of patients on or without ART using χ2 test for
categorical variables. Continuous variables were com-
pared using the two-sample t test (normal distribution)
or Wilcoxon rank-sum test (non-normal distribution).
Abnormal biochemical and haematological values were
deﬁned in accordance with the reference levels used at
HNSM. Logistic regression was used for the analysis of
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risk factors for LTFU among patients lost to programme
before a follow-up consultation after CD4 measurement.
The Cox proportional hazard model was used to calcu-
late LTFU risk factors among patients not eligible for
ART and patients on ART. Patients on ART were
included in the regression analysis by the date of ART
initiation. Follow-up time until ART initiation was
included in the analysis of patients not eligible for ART.
Variables associated with LTFU in the univariate model
(p<0.10) were included in a multivariate model. In case
of missing data, a ‘missing data’ group was made and
included in the analysis to avoid exclusion of patients.
Patients who died or were transferred to another HIV
clinic were censored by the estimated time of death and
time of transfer, respectively. The remaining patients
were censored on 1 September 2012. The incidence
rates (IR) of LTFU were calculated by Poisson regression
analysis. To include all patients in the calculation of the
overall IR of LTFU, the patients who had only been at
the clinic on the day of HIV testing were considered to
have 1 day of follow-up. All statistical analyses were
carried out using Stata IC 11.0 (StataCorp, College
Station, Texas, USA).
Ethical statement
The Bissau HIV cohort has been approved by the
National Ethics Committee in Guinea-Bissau (Parecer
NCP/No.15/2007). Upon inclusion, the patients pro-
vided a voluntary, signed and dated informed consent or
a ﬁngerprint if illiterate. The cohort has an open
approval to use data from patients’ records as long as
patient conﬁdentiality is not broken.
Stages of LTFU
Loss to programme and LTFU could occur at four differ-
ent stages (ﬁgure 1): LTFU immediately after HIV diag-
nosis (stage 1), LTFU after the ﬁrst CD4 cell count and
before a follow-up consultation (stage 2), LTFU after a
follow-up consultation for patients not eligible for ART
(stage 3) and LTFU among patients on ART (stage 4).
RESULTS
Baseline characteristics
Between June 2005 and June 2012, 4080 patients were
diagnosed with HIV at HNSM; 2724 with HIV-1, 727
with HIV-2, 486 with HIV-1/2 and 143 with an
unknown HIV type (table 1). Among the included 4080
patients, a signiﬁcantly higher percentage of women
than men were HIV-2 positive (20.2% vs 15.2%,
p<0.01), and HIV-1 positive patients were more likely to
be male than female (73.5% vs 67%, p<0.01). The
overall mean age was 37.6 years (95% CI 37.2 to 37.9);
age was signiﬁcantly lower among HIV-1 infected
(mean age 35.6 years) than HIV-2 infected patients
(mean age 43.9 years, p<0.01). The mean age of
HIV-1/2 dually infected patients was 39.4 years. In total,
3470 patients had a baseline CD4 measurement and
the median CD4 cell count was 210 cells/μL (IQR 97–
391). The HIV-2 infected patients had a signiﬁcantly
higher baseline CD4 cell count (median 260 cells/μL
(IQR 115–491)) than the HIV-1 (median 202 cells/μL
(IQR 89–362)) and HIV-1/2 dually infected patients
(median 205 cells/μL, IQR 108–368 (p<0.01)).
Figure 1 Flow chart and
outcome by 1 September 2012 of
patients included in the study.
Hønge BL, Jespersen S, Nordentoft PB, et al. BMJ Open 2013;3:e003499. doi:10.1136/bmjopen-2013-003499 3
Open Access
Patient outcome
By September 2012, 2924 (71.7%) of the included
patients had been lost to the programme: 459 (11.3%)
had died, 118 (2.9%) had been transferred to another
HIV clinic and 2347 (57.5%) had been lost to follow-up.
The overall follow-up time was 4591.1 person-years, and
the overall IR of LTFU was 51.1 (95% CI 49.1 to 53.2)
per 100 person-years. The overall median follow-up time
was 147 days (IQR 7–653). As presented in ﬁgure 1, 610
(15%) patients did not have a CD4 cell count per-
formed by the end of this study, 2351 (57.6%) patients
had initiated ART and 484 (11.9%) patients were not eli-
gible for ART.
Patients not eligible for ART had 927.1 person-years
of follow-up and the IR of LTFU was 35.2 (95% CI 31.5
to 39.2) per 100 person-years. Among patients on ART,
the follow-up time was 4012.6 person-years and median
time to ART initiation was 16 days (IQR 8–47). The IR
of LTFU was 24.9 (95% CI 23.4 to 26.5) per 100 person-
years. We stratiﬁed these ﬁndings by time period from
the date of HIV diagnosis.
Six months after HIV diagnosis, 3329 (81.6%) of all
patients diagnosed with HIV were on follow-up and 751
(18.4%) had been lost to the programme. Owing to the
deﬁnition of LTFU among patients without ART (clinic
absence for more than 210 days), all patients lost to
follow-up within the ﬁrst 6-month period were patients
on ART. In this period, 325 (8%) patients had died,
66 (1.6%) patients had been transferred and 360 (8.8%)
patients had been lost to follow-up.
In total, 3635 patients were diagnosed with HIV
before September 2011; hence, a 1-year outcome could
be evaluated. In all, 318 (8.7%) patients had died, 58
(1.6%) patients had been transferred and 1527 (42%)
patients were lost to follow-up, leaving 1732 (47.6%)
patients on follow-up.
Data on 2-year follow-up (HIV diagnosis before
September 2010) were available for 2768 patients. In
this patient group, 1715 (62%) patients had been lost to
the programme and the remaining 1053 (38%) patients
were still on follow-up. After 2 years, 258 (9.3%) patients
had died, 55 (2%) patients had been transferred and
1402 (50.1%) patients were lost to follow-up.
Risk factors of LTFU
Risk factors of LTFU among patients at stages 1–4 are pre-
sented in tables 2–5. Age below 30 years at inclusion was a
risk factor among patients at all stages. No schooling was
a signiﬁcant risk factor among patients at stages 2 and 3,
and among patients at stage 4 a positive trend was found
(HR 1.22 (95% CI 0.98 to 1.52), p=0.08). The biggest risk
factor at each stage was body mass index <18.5 kg/m2
(stage 1: OR 2.92 (95% CI 1.32 to 6.43)), male gender
(stage 2: OR 2.10 (95% CI 1.60 to 2.76)), HIV-2 infection
(stage 3: HR 2.56 (95% CI 1.91 to 3.42)) and CD4 cell
count <200 cells/μL (stage 4: HR 2.71 (95% CI 2.04 to
3.61)). Geographic site of residence was not associated
with LTFU at any stage. Catholic patients had a lower risk
of LTFU at stage 1 (OR 0.54 (95% CI 0.34 to 0.88)) and
stage 4 (HR 0.75 (95% CI 0.59 to 0.96)), and patients
with anaemia had a lower risk of LTFU at stage 3 (HR
0.32 (95% CI 0.23 to 0.45)).
DISCUSSION
This retrospective cohort study investigated the outcome
of 4080 HIV-positive patients, including a large propor-
tion of HIV-2 infected patients, diagnosed at the largest
HIV clinic in Bissau, Guinea-Bissau. Almost one-third of
the patients had been lost to the programme before the
ﬁrst consultation where ART initiation was decided, and
during the 7-year observation period more than half of
the patients had been lost to follow-up. Age below
Table 1 Baseline characteristics of all patients diagnosed
with HIV
Baseline characteristics Number n/N Percentage
Sex
Male 1345/3937 34.2
Female 2592/3937 65.8
Age stratification (years)
≤30 1271/4003 31.8
30–39 1330/4003 33.2
≥40 1402/4003 35.0
HIV type
HIV-1 2724/3937 69.2
HIV-2 727/3937 18.4
HIV-1/2 486/3937 12.3
CD4 cell count (cells/μL)
≤200 1656/3470 47.7
201–350 785/3470 22.6
>350 1029/3470 29.7
Anaemia*
Yes 2107/2486 84.8
No 379/2486 15.2
Nutritional status (kg/m2)
BMI ≤18.5 972/2902 33.5
BMI >18.5 1930/2902 66.5
Marital status
Single 990/3992 24.8
Married 2189/3992 54.8
Divorced 239/3992 6.0
Widowed 574/3992 14.4
Religion
Muslim 1614/3769 42.8
Catholic 1039/3769 27.6
Protestant 252/3769 6.7
Animist 864/3769 22.9
Schooling
Yes 2560/3904 65.6
No 1344/3904 34.4
Geographic site of residence
Bissau 2654/2969 89.4
Outside Bissau 315/2969 10.6
*Haemoglobin below normal range: men >13 and women
>12 mg/dL.
BMI, body mass index.
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30 years at inclusion was a risk factor for LTFU at all
stages. Among patients on ART, CD4 cell count <200
cells/μL was the strongest predictor of LTFU.
The main strength of this study is the large dataset
with several years of follow-up. In contrast to this study,
few sub-Saharan studies have addressed LTFU at all
stages of the ART programme and provided risk factors
of LTFU at all programme stages.17 Furthermore, active
follow-up was limited to calling patients and/or their
contact person by telephone as resource-limited settings
often do not have the possibility to conduct home visits.
This study resembles a frequent sub-Saharan setting and
the rate of LTFU and its associations may resemble that
of other clinics.
The study is limited by incomplete data among a sub-
stantial number of patients (table 1); this may have
affected the analyses in either direction. Furthermore,
HIV type discrimination was performed by SD Bioline HIV
1/2 3.0. A study from the neighbouring country Guinea-
Conakry found that SD Bioline HIV 1/2 3.0 may have over-
estimated the number of HIV-1/2 dually infected
patients;22 this was later conﬁrmed in Guinea-Bissau.23
The prevalence of patients lost to follow-up was high in
this study compared with several other African studies,9 but
the heterogenicity in the deﬁnition of LTFU makes com-
parisons between studies difﬁcult. Different LTFU deﬁni-
tions for patients on ART have been proposed ranging
from 60 days after a missed appointment to 180 days after
the date of the last visit.24 25 HIV-infected patients at
HNSM are usually supplied with ART for 30 days at a time.
LTFU among patients on ART was deﬁned as 90 days of
absence from the date of the last visit. To our knowledge,
there are no studies from sub-Saharan Africa regarding the
‘best performing’ deﬁnition of LTFU among HIV-infected
patients before ART initiation.
In this study, mortality was rather low while LTFU was
high. Other studies performed in Africa have found that
mortality was inversely related to the rate of LTFU.3
Several of the LTFU risk factors among patients on ART
were similar to the mortality risk factors among African
HIV-infected patients as described elsewhere.26 27 If a
more thorough follow-up had been performed in the
study period, the mortality rate would presumably be
higher.
Table 2 LTFU risk factors in patients without a CD4 cell count (stage 1)
Logistic regression, LTFU OR
Stage 1 Univariate analysis Multivariate analysis
LTFU risk factors OR (95% CI) p Value OR (95% CI) p Value
Sex
Male 1.42 (1.14 to 1.76) <0.01 1.16 (0.75 to 1.82) 0.50
Female 1.00 – 1.00 –
Age stratification (years)
≤30 1.00 – 1.00 –
30–39 0.50 (0.39 to 0.65) <0.01 0.46 (0.18 to 0.77) <0.01
≥40 0.62 (0.48 to 0.79) <0.01 0.48 (0.27 to 0.85) 0.01
HIV type
HIV-1 1.00 – 1.00 –
HIV-2 1.05 (0.78 to 1.41) 0.73 1.08 (0.64 to 1.83) 0.77
HIV-1/2 1.38 (0.99 to 1.91) 0.06 2.49 (1.28 to 4.85) <0.01
Nutritional status (kg/m2)
BMI≤18.5 2.97 (1.36 to 6.48) <0.01 2.92 (1.32 to 6.43) <0.01
BMI>18.5 1.00 – 1.00 –
Marital status
Single 0.99 (0.78 to 1.27) 0.96 0.66 (0.41 to 1.06) 0.08
Married 1.00 – 1.00 –
Divorced 0.74 (0.46 to 1.17) 0.20 0.65 (0.28 to 1.52) 0.32
Widowed 0.57 (0.41 to 0.80) <0.01 0.72 (0.38 to 1.37) 0.32
Religion
Muslim 1.00 – 1.00 –
Catholic 0.73 (0.57 to 0.95) 0.02 0.54 (0.34 to 0.88) 0.01
Protestant 0.40 (0.23 to 0.67) <0.01 0.54 (0.21 to 1.38) 0.20
Animist 0.88 (0.67 to 1.16) 0.37 1.09 (0.63 to 1.88) 0.76
Schooling
Yes 1.00 – – –
No 1.11 (0.89 to 1.38) 0.37 – –
Geographic site of residence
Bissau 1.00 – – –
Outside Bissau 0.34 (0.05 to 2.56) 0.30 – –
BMI, body mass index; LTFU, loss to follow-up.
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In Guinea-Bissau, many people are involved in sea-
sonal work, especially picking cashew in the country
regions, which makes them leave the capital city Bissau
during the cashew season. Furthermore, Guinea-Bissau
has been considered politically unstable for many
years. During the civil war in 1998–1999, a substantial
part of the inhabitants of Bissau ﬂed from the capital
city,28 and several coup attempts since the clinic
opened in 2005 may have inﬂuenced the degree of
LTFU. However, we do not have precise data on why
patients did not show up for appointments at the
clinic.
Age below 30 years at inclusion was a risk factor for
LTFU in all patients groups in our study. Furthermore,
no schooling and male gender were risk factors at two
stages. These variables have also been associated with
LTFU in other studies.19 29–32 Owing to the consistency
in these risk factors, special attention should be made to
avoid LTFU among these patients.
HIV-2 infection was associated with LTFU among
patients at stages 2–4. The progression of HIV-2 infec-
tion is generally much slower than that of HIV-1 and a
large proportion of HIV-2 infected individuals do not
progress to AIDS.33 A study from Gambia investigated
pretreatment LTFU, but found no association between
HIV-2 infection and LTFU,34 which is similar to LTFU at
stage 1 in our study. At the baseline characteristics,
HIV-2 was associated with a higher CD4 cell count.
Patients with a high CD4 cell count may be prone to
LTFU due to fewer HIV-related symptoms.35
Table 3 LTFU risk factors in patients without a follow-up consultation after CD4 cell count (stage 2)
Logistic regression, LTFU OR
Stage 2 Univariate analysis Multivariate analysis
LTFU risk factors OR (95% CI) p Value OR (95% CI) p Value
Sex
Male 1.47 (1.17 to 1.84) <0.01 2.10 (1.60 to 2.76) <0.01
Female 1.00 – 1.00 –
Age stratification (years)
≤30 1.00 – 1.00 –
30–39 0.74 (0.57 to 0.96) 0.03 0.58 (0.43 to 0.79) <0.01
≥40 0.71 (0.55 to 0.93) 0.01 0.46 (0.33 to 0.65) <0.01
HIV type
HIV-1 1.00 – 1.00 –
HIV-2 1.44 (1.09 to 1.90) 0.01 1.58 (1.14 to 2.19) <0.01
HIV-1/2 1.38 (0.98 to 1.93) 0.06 1.58 (1.09 to 2.30) 0.02
CD4 cell count (cells/μL)
≤200 0.59 (0.46 to 0.75) <0.01 0.56 (0.42 to 0.74) <0.01
201–350 0.41 (0.31 to 0.56) <0.01 0.45 (0.32 to 0.62) <0.01
>350 1.00 – 1.00 –
Anaemia*
Yes 1.00 (0.68 to 1.48) 1.00 – –
No 1.00 – – –
Nutritional status (kg/m2)
BMI≤18.5 1.29 (0.97 to 1.72) 0.08 1.32 (0.97 to 1.79) 0.08
BMI>18.5 1.00 – 1.00 –
Marital status
Single 0.97 (0.75 to 1.26) 0.83 – –
Married 1.00 – – –
Divorced 1.07 (0.69 to 1.66) 0.78 – –
Widowed 0.76 (0.55 to 1.06) 0.11 – –
Religion
Muslim 1.00 – 1.00 –
Catholic 0.86 (0.66 to 1.13) 0.28 0.93 (0.68 to 1.27) 0.64
Protestant 0.57 (0.35 to 0.94) 0.03 0.63 (0.36 to 1.09) 0.10
Animist 0.89 (0.66 to 1.19) 0.42 0.85 (0.61 to 1.17) 0.32
Schooling
Yes 1.00 – 1.00 –
No 1.27 (1.01 to 1.60) 0.04 1.80 (1.35 to 2.40) <0.01
Geographic site of residence
Bissau 1.00 – – –
Outside Bissau 1.22 (0.81 to 1.81) 0.34 – –
*Haemoglobin below normal range: men >13 mg/dl, women >12 mg/dl.
BMI, body mass index; LTFU, loss to follow-up.
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Anaemia seemed to have a protective effect among
patients with LTFU at stage 3. Patients at this stage had a
CD4 cell count >350 cells/μL and were not eligible for
ART according to national guidelines. Low haemoglobin
may have caused these patients to feel ill despite a
higher CD4 cell count, and thus motivated patients to
adhere to the HIV clinic. Differences in risk factors of
LTFU in patient at stages 1–4 may be due to the differ-
ences in causes of LTFU.
Various approaches have been tried to reduce the rate
of LTFU including adherence support workers36 and
mobile telephone messaging,37 but resource-limited set-
tings may not have the economy to support this without
increasing external donor support. Treating the
maximal number of new patients possible has been the
top priority for many public sector programmes, with
the possible consequence that documenting and tracing
patients with LTFU have become increasingly inad-
equate.38 Interventions that prevent LTFU in resource-
limited settings can substantially improve survival and
may be cost-effective by international criteria. HIV treat-
ment in these settings should include interventions to
prevent LTFU.39
During the last decade, the CD4 cell count threshold
for ART initiation has risen steadily. A recent study
found ART initiation among patients with a CD4 cell
count >500/μL to be beneﬁcial based on the level of
HIV RNA suppression40 and early ART initiation among
these patients has also been shown to have an enhanced
recovery of CD4 cell counts.41 Although the patient
groups are not directly comparable, the IR of LTFU
among patients not eligible for ART was higher than
that of patients on ART. However, we are not aware of
any studies evaluating the effect of early ART on LTFU
in sub-Saharan Africa.
This study does not provide the causes of LTFU
among HIV-infected patients in Guinea-Bissau. Social
workers visiting the homes of patients may be used to
Table 4 LTFU risk factors in patients not eligible for antiretroviral treatment (stage 3)
Cox regression, LTFU hazard rates (HR)
Stage 3 Univariate analysis Multivariate analysis
LTFU risk factors HR (95% CI) p Value HR (95% CI) p Value
Sex
Male 0.93 (0.72 to 1.20) 0.59 – –
Female 1.00 – – –
Age stratification (years)
≤30 1.00 – 1.00 –
30–39 0.74 (0.56 to 0.97) 0.03 0.54 (0.40 to 0.73) <0.01
≥40 0.85 (0.65 to 1.10) 0.21 0.52 (0.38 to 0.71) <0.01
HIV type
HIV-1 1.00 – 1.00 –
HIV-2 1.33 (1.04 to 1.69) 0.02 2.56 (1.91 to 3.42) <0.01
HIV-1/2 0.83 (0.56 to 1.23) 0.37 0.93 (0.61 to 1.42) 0.75
Anaemia*
Yes 0.54 (0.40 to 0.72) <0.01 0.32 (0.23 to 0.45) <0.01
No 1.00 – 1.00 –
Nutritional status (kg/m2)
BMI≤18.5 1.19 (0.91 to 1.55) 0.20 – –
BMI>18.5 1.00 – – –
Marital status
Single 0.92 (0.69 to 1.21) 0.54 – –
Married 1.00 – – –
Divorced 1.03 (0.65 to 1.62) 0.91 – –
Widowed 1.06 (0.78 to 1.44) 0.70 – –
Religion
Muslim 1.00 – – –
Catholic 0.91 (0.69 to 1.19) 0.48 – –
Protestant 1.16 (0.76 to 1.78) 0.50 – –
Animist 1.02 (0.76 to 1.36) 0.92 – –
Schooling
Yes 1.00 – 1.00 –
No 1.48 (1.18 to 1.86) <0.01 1.37 (1.07 to 1.77) 0.01
Geographic site of residence
Bissau 1.00 – – –
Outside Bissau 1.26 (0.91 to 1.75) 0.17 – –
*Haemoglobin below normal range: men >13 and women >12 mg/dL.
BMI, body mass index; LTFU, loss to follow-up.
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clarify the causes of absence,20 but due to a lack of
social security numbers, street names and house
numbers in many countries with limited resources,
follow-up is difﬁcult. Therefore, demographic surveil-
lance sites (DSS) are well suited to long-term follow-up
of HIV-infected individuals.42 We are currently undertak-
ing a nested follow-up study of the cohort patients living
in a DSS area in Guinea-Bissau.
CONCLUSION
In our study, we found a high rate of LTFU and some
variation in the risk factors of LTFU, which may be due
to different causes of LTFU at the different stages of the
HIV programme. As the mortality among patients lost to
follow-up regardless of ART status is substantial, an
increased focus on patient retention is recommended.
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